Write in a clean editor, then format for Breast Cancer Basic and Clinical Research in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Breast Cancer Basic and Clinical Research is a peer-reviewed journal published by SAGE, covering Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, Global Cancer Incidence and Screening.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Breast Cancer Basic and Clinical Research, 12(3), pp. 45–58.
Formats any DOI in Breast Cancer Basic and Clinical Research style. No sign-up. |
| Publishes research in | Breast Cancer Treatment Studies Breast Lesions and Carcinomas Global Cancer Incidence and Screening HER2/EGFR in Cancer Research Cancer Risks and Factors |
| ISSN | 1178-2234 |
| Citation impact (2-yr) | 2.1 |
| h-index | 46 |
| i10-index | 187 |
| Total citations | 8,119 |
| Article processing charge | $1,500 |
| Open access | Yes |
| Top institutions publishing here | University of Maryland, Baltimore |
| Journal website | journals.sagepub.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis. Seventeen breast cancer cell lines were harvested, fixed in formalin and made…
UNLABELLED: Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular…
Breast cancer is the most common cancer in women in both developed and developing countries and the second most common cancer in the world. Developing countries are increasingly adopting a Western lifestyle, such as changes in diet and delayed first childbirth, lower parity, and shorter periods of breastfeeding, which are important determinants of a higher…
Metastasis is the leading cause of breast cancer-associated deaths. Despite the significant improvement in current therapies in extending patient life, 30-40% of patients may eventually suffer from distant relapse and succumb to the disease. Consequently, a deeper understanding of the metastasis biology is key to developing better treatment strategies and achieving long-lasting therapeutic efficacies against…
Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Although there have been many new treatment options approved by the Food and Drug Administration for ER/PR-positive and Her2/neu-amplified metastatic breast cancer, relatively…
